Why Minerva Neurosciences, Inc.’s (NERV) Stock Is Up 6.03%
As of Tuesday, August 25, Minerva Neurosciences, Inc.’s NERV share price has surged by 6.03%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Commentary & Analysis
Why Minerva Neurosciences, Inc.’s (NERV) Stock Is Up 5.01%
As of Friday, August 21, Minerva Neurosciences, Inc.’s NERV share price has surged by 5.01%, which has investors questioning if this is right time to sell.Michael Rose
Why Minerva Neurosciences, Inc.’s (NERV) Stock Is Up 8.59%
As of Wednesday, August 19, Minerva Neurosciences, Inc.’s NERV share price has surged by 8.59%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Minerva Neurosciences, Inc.’s (NERV) Stock Is Up 15.05%
As of Friday, August 14, Minerva Neurosciences, Inc.’s NERV share price has surged by 15.05%, which has investors questioning if this is right time to sell.Michael Rose
Why Minerva Neurosciences, Inc.’s (NERV) Stock Is Up 17.47%
As of Friday, August 14, Minerva Neurosciences, Inc.’s NERV share price has surged by 17.47%, which has investors questioning if this is right time to sell.Tudor Pop
Financial Summary
| Share Statistics | NERV | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $259.3 | $298.4 | 29% |
|
| Shares Out (Mil) | 79.1 | 54.0 | 57% |
|
| Institutional Ownership | 99.0% | 93.1% | 84% |
|
| Float (Mil) | 32.6 | 41.4 | 38% |
|
| Beta | -0.11 | 0.94 | 4% |
|
| Avg Daily Volume (000s) | 382 | 504 | 55% |
|
| Price Change (52-week) |
127.2% | 62.0% | 94% |
|
| Growth | NERV | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.0% | na |
|
| Net Income (5yr) | (174.7%) | (10.0%) | 0% |
|
| EPS (5yr) | (147.7%) | 16.0% | 0 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 56.4% | (15.6%) | 95% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | 1 | 1 | |
| Current EPS | ($0.180) | ($0.570) | ($0.420) | |
| Month Ago EPS | ($0.010) | ($0.200) | na | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.010) | ($0.200) | na | |
| Year/Year Chg | 30.4% | (98.4%) | (99.6%) | |
| Financials | NERV | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($394) | ($43) | 4% |
|
| EPS (TTM) | ($14.441) | ($1.400) | 3% |
|
| Operating Cash Flow (TTM) (Mil) | ($26) | ($32) | 13% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $60 | $4 | 40% |
|
| Enterprise Value (Q1) (Mil) | $228 | $186 | 27% |
|
| Valuation | NERV | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.89 | na |
|
| P/E | na | 19.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | NERV | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.6% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (628.4%) | (47.6%) | 0% |
|
| ROE | 321.4% | (55.0%) | 99% |
|
| Liabilities to Assets | 312.0% | 29.5% | 99% |
|
| F-Score | 2 | 3 | na |
|
Minerva Neurosciences, Inc. did not pass any screens on 8/26/2026.
